Literature DB >> 27207549

Discovery of a Genetic Metabolic Cause for Mauriac Syndrome in Type 1 Diabetes.

Michael J MacDonald1, Noaman M Hasan2, Israr-Ul H Ansari2, Melissa J Longacre2, Mindy A Kendrick2, Scott W Stoker2.   

Abstract

A mechanistic cause for Mauriac syndrome, a syndrome of growth failure and delayed puberty associated with massive liver enlargement from glycogen deposition in children with poorly controlled type 1 diabetes, is unknown. We discovered a mutation in the catalytic subunit of liver glycogen phosphorylase kinase in a patient with Mauriac syndrome whose liver extended into his pelvis. Glycogen phosphorylase kinase activates glycogen phosphorylase, the enzyme that catalyzes the first step in glycogen breakdown. We show that the mutant subunit acts in a dominant manner to completely inhibit glycogen phosphorylase kinase enzyme activity and that this interferes with glycogenolysis causing increased levels of glycogen in human liver cells. It is known that even normal blood glucose levels physiologically inhibit glycogen phosphorylase to diminish glucose release from the liver when glycogenolysis is not needed. The patient's mother possessed the same mutant glycogen phosphorylase kinase subunit, but did not have diabetes or hepatomegaly. His father had childhood type 1 diabetes in poor glycemic control, but lacked the mutation and had neither hepatomegaly nor growth failure. This case proves that the effect of a mutant enzyme of glycogen metabolism can combine with hyperglycemia to directly hyperinhibit glycogen phosphorylase, in turn blocking glycogenolysis causing the massive liver in Mauriac disease.
© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27207549     DOI: 10.2337/db16-0099

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  7 in total

1.  Persistent lactic acidosis in the Mauriac syndrome in type 1 diabetes mellitus.

Authors:  Abinash Subedi; Vishnu Charan Suresh Kumar; Anuj Sharma; Gilles Hoilat; Savio John
Journal:  Proc (Bayl Univ Med Cent)       Date:  2021-01-11

Review 2.  Growth in patients with type 1 diabetes.

Authors:  Deborah M Mitchell
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-02       Impact factor: 3.243

3.  Elevated lactate in Mauriac syndrome: still a mystery.

Authors:  Brice Touilloux; Henri Lu; Belinda Campos-Xavier; Andrea Superti-Furga; Michael Hauschild; Thérèse Bouthors; Christel Tran
Journal:  BMC Endocr Disord       Date:  2021-08-21       Impact factor: 2.763

4.  Persistent hyperlactatemia in decompensated type I diabetes with hepatic glycogenosis and hepatomegaly: Mauriac syndrome: a case report.

Authors:  Waheed Dolip; Eric Bourmanne; Charlotte Van Homwegen; Marc Van Nuffelen
Journal:  J Med Case Rep       Date:  2022-06-02

Review 5.  Other types of diffuse liver disease: is there a way to do it?

Authors:  Hilton Leao Filho; Camila Vilela de Oliveira; Natally Horvat
Journal:  Abdom Radiol (NY)       Date:  2020-11

Review 6.  Glycogenic hepatopathy: A narrative review.

Authors:  Jagannath M Sherigar; Joline De Castro; Yong Mei Yin; Debra Guss; Smruti R Mohanty
Journal:  World J Hepatol       Date:  2018-02-27

7.  Reversible severe glycogenic hepatopathy in type 1 diabetes.

Authors:  Jan de Laffolie; Clemens Kamrath; Diana Burchert; Claudia Böttcher; Stefan Alexander Wudy; Klaus-Peter Zimmer
Journal:  Wien Med Wochenschr       Date:  2021-01-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.